Targeted therapy in eosinophilic chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a common and preventable airway disease causing significant worldwide mortality and morbidity. Lifetime exposure to tobacco smoking and environmental particles are the two major risk factors. Over recent decades, COPD has become a growing public health...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2021-04-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/7/2/00437-2020.full |
| _version_ | 1818862481657823232 |
|---|---|
| author | Mathieu Fieldes Chloé Bourguignon Said Assou Amel Nasri Aurélie Fort Isabelle Vachier John De Vos Engi Ahmed Arnaud Bourdin |
| author_facet | Mathieu Fieldes Chloé Bourguignon Said Assou Amel Nasri Aurélie Fort Isabelle Vachier John De Vos Engi Ahmed Arnaud Bourdin |
| author_sort | Mathieu Fieldes |
| collection | DOAJ |
| description | Chronic obstructive pulmonary disease (COPD) is a common and preventable airway disease causing significant worldwide mortality and morbidity. Lifetime exposure to tobacco smoking and environmental particles are the two major risk factors. Over recent decades, COPD has become a growing public health problem with an increase in incidence. COPD is defined by airflow limitation due to airway inflammation and small airway remodelling coupled to parenchymal lung destruction. Most patients exhibit neutrophil-predominant airway inflammation combined with an increase in macrophages and CD8+ T-cells. Asthma is a heterogeneous chronic inflammatory airway disease. The most studied subtype is type 2 (T2) high eosinophilic asthma, for which there are an increasing number of biologic agents developed. However, both asthma and COPD are complex and share common pathophysiological mechanisms. They are known as overlapping syndromes as approximately 40% of patients with COPD present an eosinophilic airway inflammation. Several studies suggest a putative role of eosinophilia in lung function decline and COPD exacerbation. Recently, pharmacological agents targeting eosinophilic traits in uncontrolled eosinophilic asthma, especially monoclonal antibodies directed against interleukins (IL-5, IL-4, IL-13) or their receptors, have shown promising results. This review examines data on the rationale for such biological agents and assesses efficacy in T2-endotype COPD patients. |
| first_indexed | 2024-12-19T10:00:33Z |
| format | Article |
| id | doaj.art-cdab6cf8e2214fd3b4abbfc8ba197cbc |
| institution | Directory Open Access Journal |
| issn | 2312-0541 |
| language | English |
| last_indexed | 2024-12-19T10:00:33Z |
| publishDate | 2021-04-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj.art-cdab6cf8e2214fd3b4abbfc8ba197cbc2022-12-21T20:26:39ZengEuropean Respiratory SocietyERJ Open Research2312-05412021-04-017210.1183/23120541.00437-202000437-2020Targeted therapy in eosinophilic chronic obstructive pulmonary diseaseMathieu Fieldes0Chloé Bourguignon1Said Assou2Amel Nasri3Aurélie Fort4Isabelle Vachier5John De Vos6Engi Ahmed7Arnaud Bourdin8 IRMB, INSERM, Montpellier University Hospital, Montpellier, France IRMB, INSERM, Montpellier University Hospital, Montpellier, France IRMB, INSERM, Montpellier University Hospital, Montpellier, France IRMB, INSERM, Montpellier University Hospital, Montpellier, France Dept of Respiratory Diseases, Montpellier University Hospital, INSERM, Montpellier, France Dept of Respiratory Diseases, Montpellier University Hospital, INSERM, Montpellier, France IRMB, INSERM, Montpellier University Hospital, Montpellier, France Dept of Respiratory Diseases, Montpellier University Hospital, INSERM, Montpellier, France Dept of Respiratory Diseases, Montpellier University Hospital, INSERM, Montpellier, France Chronic obstructive pulmonary disease (COPD) is a common and preventable airway disease causing significant worldwide mortality and morbidity. Lifetime exposure to tobacco smoking and environmental particles are the two major risk factors. Over recent decades, COPD has become a growing public health problem with an increase in incidence. COPD is defined by airflow limitation due to airway inflammation and small airway remodelling coupled to parenchymal lung destruction. Most patients exhibit neutrophil-predominant airway inflammation combined with an increase in macrophages and CD8+ T-cells. Asthma is a heterogeneous chronic inflammatory airway disease. The most studied subtype is type 2 (T2) high eosinophilic asthma, for which there are an increasing number of biologic agents developed. However, both asthma and COPD are complex and share common pathophysiological mechanisms. They are known as overlapping syndromes as approximately 40% of patients with COPD present an eosinophilic airway inflammation. Several studies suggest a putative role of eosinophilia in lung function decline and COPD exacerbation. Recently, pharmacological agents targeting eosinophilic traits in uncontrolled eosinophilic asthma, especially monoclonal antibodies directed against interleukins (IL-5, IL-4, IL-13) or their receptors, have shown promising results. This review examines data on the rationale for such biological agents and assesses efficacy in T2-endotype COPD patients.http://openres.ersjournals.com/content/7/2/00437-2020.full |
| spellingShingle | Mathieu Fieldes Chloé Bourguignon Said Assou Amel Nasri Aurélie Fort Isabelle Vachier John De Vos Engi Ahmed Arnaud Bourdin Targeted therapy in eosinophilic chronic obstructive pulmonary disease ERJ Open Research |
| title | Targeted therapy in eosinophilic chronic obstructive pulmonary disease |
| title_full | Targeted therapy in eosinophilic chronic obstructive pulmonary disease |
| title_fullStr | Targeted therapy in eosinophilic chronic obstructive pulmonary disease |
| title_full_unstemmed | Targeted therapy in eosinophilic chronic obstructive pulmonary disease |
| title_short | Targeted therapy in eosinophilic chronic obstructive pulmonary disease |
| title_sort | targeted therapy in eosinophilic chronic obstructive pulmonary disease |
| url | http://openres.ersjournals.com/content/7/2/00437-2020.full |
| work_keys_str_mv | AT mathieufieldes targetedtherapyineosinophilicchronicobstructivepulmonarydisease AT chloebourguignon targetedtherapyineosinophilicchronicobstructivepulmonarydisease AT saidassou targetedtherapyineosinophilicchronicobstructivepulmonarydisease AT amelnasri targetedtherapyineosinophilicchronicobstructivepulmonarydisease AT aureliefort targetedtherapyineosinophilicchronicobstructivepulmonarydisease AT isabellevachier targetedtherapyineosinophilicchronicobstructivepulmonarydisease AT johndevos targetedtherapyineosinophilicchronicobstructivepulmonarydisease AT engiahmed targetedtherapyineosinophilicchronicobstructivepulmonarydisease AT arnaudbourdin targetedtherapyineosinophilicchronicobstructivepulmonarydisease |